Sep 24 2024
Narcolepsy Type 2: Orexin Replacement Therapy

Because partial or complete Orexin receptor deficiency plays an important role in the development of EDS, orexin replacement therapy may improve EDS through a pathophysiology-directed mechanism of action. We are currently investigating a new novel drug that acts to help address the deficiency of orexin-2 receptor agonists that may address the spectrum of narcolepsy symptoms and have greater efficacy than currently approved drugs for EDS

Study Details

• A phase-3, randomized, double-blind clinical research study
• Participants will last up to 52 weeks
• Two mandatory overnight PSG in our sleep clinic
• Mandatory in office visits every 4 weeks

Criteria

• Between 18 and 70 years old.
• Medically Diagnosed with Narcolepsy Type 2
• Has residual EDS
• Must be willing to discontinue any prescribed medications for managing narcolepsy symptoms at least 14 days prior to study start date.
• BMI between 18 and 35
• Meet additional eligibility criteria

Eligible subjects receive compensation for their time and participation

If you are interested in learning more or want to participate, please visit Current Clinical Trials | Intrepid Research (intrepidresearchoh.com)